Meeting
2022 ASCO Quality Care Symposium
Real-world versus clinical trial CAR T outcomes among patients diagnosed with diffuse large B-cell lymphoma.
Authors
Kaitlyn McBride
Qualia Bio, Los Angeles, CA
Kaitlyn McBride, Sophie Snyder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 413)
DOI
10.1200/JCO.2022.40.28_suppl.413
Abstract #
413
Poster Bd #
F16
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
First Author: Lindsey Fitzgerald
Poster
2017 ASCO Annual Meeting
Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
First Author: Bijal D. Shah
Poster
2024 ASCO Annual Meeting
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
First Author: Armin Ghobadi
Poster
2023 ASCO Annual Meeting
Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).
First Author: Matthew J. Frigault